ABSTRACT
Background
House dust mites (HDMs) are the most important respiratory allergen sources. In temperate regions, the genus Dermatophagoides predominates, whereas in sub‐tropical and tropical regions, the genus Blomia is also of high importance. There is only limited IgE cross‐reactivity between Dermatophagoides and Blomia.
Objective
To produce a chip containing purified microarrayed Blomia tropicalis (Blo t) and Dermatophagoides pteronyssinus allergens (Der p) capable of identifying patients with a genuine Blo t or Der p IgE sensitisation, co‐sensitisation and/or cross‐sensitisation.
Methods
Chips containing seven purified Blo t and thirteen Der p allergens were generated by microarray technology and tested for IgE and IgG reactivity in HDM‐sensitised patients from Blo t‐endemic (group 1: n = 115) and Blo t‐non‐endemic (group 2: n = 33) regions. IgE cross‐reactivity was analysed by IgE inhibition studies.
Results
IgE levels to Blo t 2, Blo t 5, Blo t 10, Blo t 12 and Blo t 21 were significantly higher in HDM‐sensitised patients from Blo t‐endemic as compared to patients from Blo t‐non‐endemic regions, whereas the opposite was observed for IgE to Der p 2 and Der p 21 in patients from Blo t‐non‐endemic regions. An algorithm based on IgE reactivity profiles and allergen‐specific IgE levels capable of discriminating genuine sensitisation to Blo t and Der p or co‐sensitisation was established. In HDM‐sensitised patients from Blo t‐endemic regions, each of the aforementioned sensitisation profiles was observed, whereas in HDM‐sensitised patients from Blo t‐non‐endemic regions, only genuine sensitisations to Der p and co‐sensitisations to Blo t and Der p were observed.
Conclusion
The algorithm based on microarrayed Blo t and Der p allergens for discrimination of Blo t and Der p sensitisation may support prescription of allergen‐specific immunotherapy. At minimum, it will be helpful in understanding disease aetiology and for fine resolution mapping of allergic reactivities in HDM sensitisation.
Keywords: allergen microarray, allergens, allergy, asthma, Blomia tropicalis, Dermatophagoides
This study established a microarray containing a representative panel of purified Blo t and Der p allergens for the identification of patients sensitised to Blo t and/or Der p. Results indicate that the microarray based on Blo t and Der p allergens is a useful tool for the identification of Blo t‐ and/or Der p‐sensitised patients. The microarray may be used as a decision support for the prescription of allergen‐specific immunotherapy for Der p and/or Blo t allergy. AIT, allergen immunotherapy; Blo t, Blomia tropicalis; Der p, Dermatophagoides pteronyssinus; IgE, immunoglobulin E.

Abbreviations
- ELISA
enzyme‐linked immunosorbent assay
- HDM
house dust mite
- kUA/L
kilo units antigen per litre
- OD
optical density
- rBlo t
recombinant Blomia tropicalis
- rDer p
recombinant Dermatophagoides pteronyssinus
- SPT
skin prick test
1. Introduction
House dust mite allergens belong to the most frequent elicitors of respiratory allergy such as rhinitis and severe forms of asthma as well as allergic skin manifestations [1]. In temperate climates, the genus Dermatophagoides predominates whereas in sub‐tropical and tropical regions, the genus Blomia is of high importance [2, 3]. Several studies report IgE sensitisation to Blomia in the southern parts of the USA [4], in South America [5], the equatorial regions of Africa [6, 7], Thailand [8, 9], Malaysia, Singapore, Taiwan and China [10, 11, 12]. The clinical relevance of IgE sensitisation to Blomia tropicalis is underlined by results obtained in controlled provocation studies demonstrating that Blomia tropicalis can elicit eye and/or respiratory symptoms of allergy [13, 14]. Furthermore, IgE sensitisation to Blomia tropicalis has been found to be associated with respiratory symptoms of allergy and even severe forms of allergic asthma in patients from Blo t‐endemic regions [14]. Surprisingly, IgE sensitisation to Blomia tropicalis by skin prick testing has been reported in a European population which is from a Blo t‐non‐endemic region [15]. Even studies performed with recombinant Blomia tropicalis allergens indicate that HDM‐sensitised patients from Blo t‐non‐endemic regions are quite frequently sensitised to Blo t allergens [15, 16]. There are currently 26 Blomia tropicalis allergens listed in the IUIS Allergen Nomenclature Database (https://allergen.org/search.php?allergenname=Blo+t&allergensource=&TaxSource=&TaxOrder=&foodallerg=all&bioname= accessed on 28 January 2026) [17]. Immunological studies performed with allergen extracts and especially with purified recombinant allergens indeed indicate that there is only limited IgE cross‐reactivity between certain Blo t allergens and Der p allergens. For example, partial IgE cross‐reactivity between Blo t 2 and Der p 2, between Blo t 5 and Der p 5 and between Blo t 21 and Der p 21 has been observed [18, 19, 20, 21]. For the treatment of HDM allergies, AIT vaccines based on HDM allergen extracts and Blo t allergen extracts are available and it is therefore important to identify patients who are genuinely sensitised either to Der p or Blo t or co‐sensitised to Der p and Blo t [22, 23]. Accordingly, the goal of our study was to establish a microarray containing a representative panel of purified Blo t and Der p allergens for the identification of patients sensitised to Blo t and/or Der p. In order to study the utility of this allergen microarray, we collected sera from HDM‐sensitised patients from Blo t‐endemic and Blo t‐non‐endemic regions and tested these sera for IgE and IgG reactivity to the microarrayed Blo t and Der p allergens. Furthermore, we performed IgE inhibition studies with purified Blo t and Der p allergens to inhibit IgE binding to the microarrayed allergens to establish an algorithm based on IgE profiles (allergen specific IgE reactivity and levels) for distinguishing between Blo t/Der p IgE cross reactivity and co‐sensitisation. Our results indicate that the microarray based on Blo t and Der p allergens is a useful tool for the identification of Blo t‐ and/or Der p‐sensitised patients and may be used as a decision support for the prescription of allergen‐specific immunotherapy for Der p and/or Blo t allergy.
2. Methods
2.1. Patients' Demographics
Tables 1, S1 and S2 summarise the demographic, serologic and clinical data of patients whose sera were analysed. Sera were obtained from two groups of patients: Group 1 were HDM‐sensitised patients from Blo t‐endemic regions who were characterised by positive skin prick test (SPT) reactions to HDM extracts and/or by a positive radioallergosorbent test to Der p. Sensitisations to other allergen sources were determined by SPT and by detailed case history (Tables 1 and S1). Allergic symptoms (rhinitis, asthma) related to HDM were recorded by medical history but information regarding skin symptoms was not available for all group 1 patients and therefore is not included in Tables 1 and S1. Group 2 HDM‐sensitised patients from Blo t‐non‐endemic regions were characterised by a positive radioallergosorbent test and a positive SPT reaction. For these patients, symptoms were also recorded upon controlled allergen exposure to Der p but this was not the basis for their selection and inclusion in our study [24]. Only medical history, SPT and serology were considered. Furthermore, sensitisations to other allergen sources were determined by SPT and case history (Tables 1 and S2). Pseudonymised residual serum samples were analysed with permission from the Ethics Committee of the Medical University of Vienna (EK 1641/2014).
TABLE 1.
Demographic and clinical characterisation of HDM‐sensitised patients from Blo t–endemic and Blo t‐non‐endemic regions.
| Group 1 | Group 2 | |
|---|---|---|
| HDM‐ sensitised patients from Blo t‐endemic regions (n = 115) | HDM‐ sensitised patients from Blo t‐non‐endemic regions (n = 33) | |
| M/F | 44/71 | 14/19 |
| Age mean | 25.7 | 24.7 |
| Rhinitis | N = 115 (100%) | N = 33 (100%) |
| Asthma | N = 38 (33%) | N = 16 (48%) |
| Dermatitis | n.a. | N = 21 (64%) |
2.2. Allergen Extracts
To prepare allergen extracts suitable for serological and cellular assays, aliquots of 0.3 g of Blo t or Der p purified mites (Allergon, Angelholm, Sweden) were solubilised in 5 mL PBS (137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 2 mM KH2PO4, pH 7.4) and immediately homogenised using an ULTRA‐TURRAX (IKA T18, Staufen, Germany) for 1.5 min on ice, extracted overnight by shaking at 4°C. Extracts were then centrifuged in a HITACHI High‐Speed refrigerated centrifuge CR 22N (Hitachi Koki Co. Ltd., Tokyo, Japan) using a R20A2 rotor at 10,000 rpm for 15 min at 4°C. Supernatants were collected, aliquoted and frozen immediately at −80°C. Protein concentrations were measured using Pierce BCA Protein Assay Kits (ThermoFisher Scientific, Massachusetts, USA). Different amounts of the extracts (20, 15, 10 and 5 μg) were separated by 14% SDS‐PAGE and stained with Coomassie Brilliant Blue (ThermoFisher Scientific) to study the quality of the extracts.
2.3. Allergen‐Specific Polyclonal Rabbit Antisera
Allergen‐specific polyclonal antisera for rDer p 2 [25], rDer p 5, rDer p 21 [26], rBlo t 5 and rBlo t 21 (this study) were obtained by immunising rabbits three times in monthly intervals with 200 μg of each recombinant allergen once in Freund's complete and twice in Freund's incomplete adjuvant. Rabbit immunisations were performed at Charles River Laboratories under legal policy and ethics permission (Chatillon‐sur‐Chalaronne, France, https://www.criver.com/).
2.4. ELISA
ELISA plates (96 wells) (Greiner Bio‐One GmbH, Kremsmünster, Austria) were coated with 3 μg/mL of purified allergens dissolved in 0.1 M sodium bicarbonate buffer pH 9.6 (100 μL per well) or 30 μg/mL of Der p or Blo t extract overnight at 4°C. Human serum albumin (3 μg/mL HSA) was used as a negative control. After washing the plates with TBST (20 mM Tris, 150 mM NaCl, 0.1% (v/v) Tween 20, pH 8.0), they were blocked with TBST/3% BSA (200 μL per well) for 3 h at 37°C. Different dilutions (1:100, 1:200, 1:400, 1:800, 1:1600, 1:3200 in TBST/1% BSA) of rabbit sera specific for Der p and Blo t allergens or normal rabbit sera were added, and plates were incubated overnight at 4°C. After washing the plates with TBST, 1:2000 (TBST/1% BSA) diluted alkaline phosphatase‐labelled goat anti‐rabbit IgG antibodies (BD Biosciences, Franklin Lakes, New Jersey) were added to the plates and incubated for 1 h at 37°C and for another hour at 4°C. Plates were washed, and alkaline phosphatase substrate (i.e., one Sigma 104 tablet, Sigma‐Aldrich, St. Louis, MO was dissolved in 5 mL of ELISA substrate buffer, 100 mL diethanolamine, 3 M NaN3, pH 9.8) was added to start the colour reaction which was read with ELISA reader (InfiniteF50, Tecan Trading AG, Switzerland) at a wavelength of 405 nm. OD values obtained for HSA were used as cut‐off.
Patients' IgE reactivity to allergens was determined by ELISA using sera diluted 1:5 in TBST/1% BSA. Coating, blocking and washing was done as described for ELISA experiments carried out for rabbit antibodies. Bound IgE antibodies were detected with a mouse monoclonal alkaline phosphatase‐labelled anti‐human IgE antibody (Pharmingen, San Diego, CA) diluted 1:1000 in TBST/0.5% BSA. Results are expressed as means of duplicates with a deviation of < 10%. The cut‐off value of IgE reactivity was defined as mean OD plus three standard deviations of 13 negative patients' sera and was 0.047.
2.5. Sequence Comparisons
The amino acid sequences of allergens (Blo t 2, GenBank: AAQ73483.1; Der p 2, GenBank: AAF86462.1; Blo t 5, GenBank: AAD10850.1; Der p 5, GenBank: AAB32842.1; Blo t 8, GenBank: ACV04860.1; Der p 8, GenBank: AAB32224.1; Blo t 10, GenBank: ABU97466.1; Der p 10, GenBank: CAA75141.1; Blo t 21, GenBank: AAX34047.1; Der p 21, GenBank: ABC73706.1) were compared and aligned using the BLASTp programme. They were aligned and coloured to show sequence identities and similarities of conserved amino acids as described [27].
2.6. Expression, Purification and Characterisation of Recombinant Blo t and HDM Allergens
Synthetic genes which were codon‐optimised for Escherichia coli expression of the amino sequences of Blo t 2 (GenBank: AAQ73483.1), Blo t 5 (GenBank: AAD10850.1), Blo t 8 (GenBank: ACV04860.1), Der p 8 (GenBank: AAB32224), Blo t 10 (GenBank: ABU97466.1), Blo t 12 (GenBank: AAA78904.1), Blo t 13 (GenBank: AAC80579.1), Blo t 21 (GenBank: AAX34047.1) and Der p 29 (GenBank: QAT18640) were obtained from ATG Biosynthetics, Merzhausen, Germany. The DNAs contained a C‐terminal sequence coding for a hexahistidine tag followed by a stop codon and a 3′ EcoRI restriction site and a 5′ NdeI restriction site containing the sequence coding for the start ATG sequence. These DNAs were cloned into the NdeI and EcoRI sites of plasmid pET17b and transformed into Escherichia coli strain BL21 (DE3) Gold (ThermoFisher Scientific) for protein expression. Transformed E. coli were used to inoculate 400 mL cultures of LB‐Amp medium (4 g Peptone, 4 g NaCl, 2 g yeast extract, pH 7.4, 100 μg/mL Ampicillin, Roth, Karlsruhe, Germany). Protein expression was induced by adding isopropyl β‐d‐1‐thiogalactopyranoside (IPTG) (Roth) to a final concentration of 0.5 mM once the OD reached 0.6 and culturing at 180 rpm was continued for 3 h at 37°C. Then cultures were centrifuged at 6800× g for 20 min at 4°C. The supernatants were discarded and the pellets were redissolved in either native (Blo t 5, Blo t 8, Blo t 10, Blo t 21) or denaturing lysis buffer (Blo t 2, Blo t 12, Blo t 13, Der p 8 and Der p 29) (Qiagen, Hilden Germany), homogenised using an ULTRA TURRAX (IKA) on ice and then centrifuged again at 38,900xg for 20 min at 4°C. The supernatants were then incubated with 1 mL Ni‐NTA (Qiagen) at 4°C overnight. Purification of recombinant proteins under native or denaturing elution buffers was performed as described (Qiagen) [28, 29]. The purity of the purified recombinant allergens was confirmed by sodium dodecyl sulphate‐polyacrylamide gel electrophoresis (SDS PAGE) and Coomassie Brilliant Blue staining. A Bicinchoninic Acid Assay (BCA) Protein Assay Kit (ThermoFisher Scientific) was used to determine the concentration of each allergen. The molecular mass of the allergens was determined by matrix‐assisted laser desorption/ionisation time‐of‐flight mass spectrometry on a Shimadzu Biotech Axima Confidence instrument (Shimadzu, Kyoto, Japan). For calibration, carbonic anhydrase (Bruker Daltonics, Billerica, Massachusetts) was used. The mass difference between calibrators for the same protein was in the range of 100–200 Da.
The recombinant mite allergens were analysed by circular dichroism (CD) spectroscopy on a JASCO J‐810 Spectropolarimeter (Japan Spectroscopic Co. Tokyo, Japan). The measurements were performed in a quartz cuvette with a path length of 0.1 cm and the spectra were recorded from 195 to 260 nm with a resolution of 0.5 nm at a scan speed of 50 nm/min in triplicates. Mean residue ellipticities were calculated at the corresponding wavelengths by normalising with the concentration and the number of amino acid residues. Secondary structures derived from the CD data were compared with the three‐dimensional structures, which were available for Blo t 5 (PDB: 2JMW; [30]), Blo t 8 (PDB: 4Q5N; [31]), Blo t 12 (PDB: AF_AFQ17282F1; [32]), Blo t 13 (PDB: 8WKH; [33]) and Blo t 21 (PDB: 2LM9; [34]). For the other allergens (i.e., Blo t 2, Blo t 10) structures were predicted using AlphaFold2 [35] on a local installation of the ColabFold server [36].
The recombinant Dermatophagoides pteronyssinus allergens (Der p allergens: rDer p 4 (GenBank: AAD38942), rDer p 5 (GenBank: CAA35692), rDer p 7 (GenBank: AAA80264), rDer p 10 (GenBank: CAA75141), rDer p 18 (GenBank: AAY84563), rDer p 20 (GenBank: ACD50950), rDer p 21 (GenBank: ABC73706), rDer p 23 (GenBank: ACB46292) and rDer p 37 (GenBank: AVD73319)) were produced and characterised as described [26, 28, 37, 38, 39, 40, 41, 42, 43]. nDer p 1 and nDer p 2 were purchased from Citeq (Groningen, Netherlands) and Inbio (Charlottesville, VA), respectively.
2.7. Allergen Microarrays
Allergens were dissolved in a concentration of 0.5–1 mg/mL in phosphate buffer (75 mM NaH2PO4, pH 8.4) and spotted in triplicates onto glass slides (Paul Marienfeld GmbH & Co. KG, Lauda‐Königshofen, Germany) using a SciFlexArrayer S12 (Scienion AG, Berlin, Germany) [44]. Slides with allergens printed on them were kept for 15 h at room temperature at 75% humidity and saturated with blocking buffer (PBS containing 0.1% Tween 20 and 0.2% ethanolamine). A liquid plate sealer (CANDOUR Bioscience GmbH, Wangen, Germany) was used for protein preservation and slides were then dried by centrifugation (160× g, 3 min) using a Sigma 2–7 centrifuge in combination with a MTP‐11113 rotor (Sigma Laborzentrifugen GmbH, Osterode am Harz, Germany).
Then chips were washed with PBS, 1% Tween‐20 and centrifuged at 160× g for 3 min before aliquots of thirty microliters of undiluted serum samples were added to each array for 2 h. One array was incubated with a serum pool (i.e., calibrator serum) containing defined IgE levels to several of the allergens present on the chip as measured by ImmunoCAP (Thermo Fisher Scientific/Phadia, Uppsala, Sweden). Sample diluent (Phadia) was used as a negative control. Slides were then washed and bound IgE was detected with a mouse monoclonal anti‐human IgE antibody (Roche, Basel, Switzerland) labelled with DyLight 550‐2xPEG NHS Ester (Thermo Fisher Scientific) in the dark for 30 min at room temperature.
For detection of allergen‐specific IgG, sera were diluted 1:50 in ImmunoCAP Specific IgA/IgG Sample Diluent (Phadia, Uppsala, Sweden). Diluted sera, a calibrator serum for IgG and sample diluent for positive and negative control purposes, respectively were added and slides were processed as described for IgE detection. Bound IgG was detected with affiniPure F(ab′)2 goat anti‐huIgG (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) labelled with DyLight 550‐2xPEG NHS Ester (Thermo Fisher Scientific).
Microarrays were read in a confocal laser scanner TECAN Power Scanner (Grödig, Austria) and images were analysed with the Mapix software (Innopsys, Carbonne, France). Levels of allergen‐specific IgE antibodies were reported in ISU‐E and levels of allergen‐specific IgG antibodies in ISU‐G (ISAC Standardised Units).
2.8. Microarray IgE Inhibition Experiments
Undiluted patients' sera (15 μL) were pre‐incubated with aliquots of 15 μL of either a mix containing 3 μg of each of the Blo t allergens (rBlo t 2, rBlo t 5 and rBlo t 21), a mix containing 3 μg of each of the Der p allergens (Der p 2, Der p 5 and Der p 21) or, as negative control, an aliquot of 15 μL containing 9 μg of the control allergen Bet v 1 [45, 46] overnight at 4°C. The allergen concentrations used were shown to be sufficient for complete adsorption. Each of the pre‐incubated serum aliquots was then tested for IgE reactivity to an allergen microarray and bound IgE antibodies were detected as described for the methods ‘Allergen microarrays’.
2.9. Statistical Analysis
The graphical representations were prepared using GraphPad Prism 5.0 (GraphPad Software Inc., La Jolla, CA, USA). To analyse IgE and IgG values between the two populations, Mann–Whitney U test was used. p values < 0.05 were considered statistically significant (*p < 0.05, **p < 0.01, ***p < 0.001).
3. Results
3.1. Demographic and Clinical Characterisation of HDM‐Sensitised Patients From Blo t‐Endemic and Blo t‐Non‐Endemic Regions
We included in our study sera from 115 HDM‐sensitised patients from Blo t‐endemic regions that is three equatorial countries with tropical climate (Gabon, Colombia, Thailand) (Group 1) and 33 HDM‐sensitised patients from Blo t‐non‐endemic regions of Austria (Middle Europe) (Group 2). Patients were born and grew up in the region. Age (Group 1: mean age 25.7 years; Group 2: mean age 24.7 years) and gender (Group 1: 44 males, 71 females; Group 2: 14 males, 19 females) distribution in the two groups was comparable (Tables 1, S1 and S2). Allergic symptoms in group 1 and group 2 were also comparable (Group 1: rhinitis 100%, asthma 33%; Group 2: rhinitis 100%, asthma 48%, dermatitis 64%) (Tables 1, S1 and S2). The frequency of atopic dermatitis could not be compared because this information was not available for all group 1 patients. The following additional sensitisations in group 1 patients were found: cockroach 83%, cat 62%, dog 49%, grass 41%, mould 15%, peanut 3%. For group 2, the following additional sensitisations were recorded: birch 57%, grass 54%, cat 54%, mugwort 12%, rye 12%, dog 12%, horse 9%, hazelnut 9%. Allergic sensitisation to Blomia tropicalis was not specifically assessed by current forms of allergen extract based skin testing and serology in all patients and is therefore not indicated.
3.2. Testing of Antibodies Specific for Blo t and Der p Allergens Suggests That Dermatophagoides and Blomia Tropicalis Are Antigenically Different
We used allergen‐specific polyclonal antisera raised against recombinant Der p 2, Der p 5, Der p 21, Blo t 5 and Blo t 21 to search for cross‐reactive allergens in Blo t and Der p allergen extracts. Figure S1 shows that the aqueous Blo t and Der p allergen extracts contained intact proteins. In both extracts, major bands at approximately 25 kDa and 12 kDa, presumably representing group 1 and group 2 allergens, were observed (Figure S1). The Der p and Blo t allergen extracts were then studied regarding the presence of allergens/cross‐reactive allergens by ELISA using the aforementioned polyclonal allergen‐specific antisera (Figure 1). Anti‐Der p 2 antibodies strongly reacted with Der p extract but also with Blo t extract at a lower serum dilution (i.e., 1:100) (Figure 1A). The Der p 5 specific antiserum did not react with Blo t or Der p extract even at very low serum dilutions, while Der p 21 specific antibodies reacted to Blo t extract (Figure 1C,E). Likewise, Blo t 5‐ and Blo t 21‐specific antibodies reacted with Blo t extract but showed no reactivity with Der p extract (Figure 1B,D). Each of the antisera reacted strongly with the purified allergens against which they were raised (Figure 1A–E). No relevant reactivity of normal rabbit antibodies with Der p and Blo t extract was observed (Figure 1F).
FIGURE 1.

Reactivity of different dilutions (x‐axes) of rabbit antisera raised against rDer p 2 (A), rBlo t 5 (B), rDer p 5 (C), rBlo t 21 (D), rDer p 21 (E) and of a normal rabbit antiserum (NRS) (F) to extracts (D. pteronyssinus extract: Der p; B. tropicalis extract: Blo t) and antigens (rBlo t 2, rDer p 2, rBlo t 5, rDer p 5, rBlo t 21, rDer p 21) as indicated in figures. Optical density (OD) values corresponding to antibody levels are shown on the y‐axes (averages of triplicates with variations of < 10%).
3.3. Low Degree of Sequence Identity Between Most of the Blo t and Der p Allergens
There is only a relatively low degree of sequence identity between most of the Blo t and Der p allergens (Sequence identities: Blo t 2 vs. Der p 2: 42.03%, Blo t 5 vs. Der p 5: 45.39%, Blo t 8 vs. Der p 8: 36.65%, Blo t 21 vs. Der p 21: 40.41%) (Figure S2). This finding is in agreement with the low reactivity of antisera specific for Der p allergens and Blo t allergens with Blo t and Der p extract, respectively. Furthermore, there is only modest IgE cross‐reactivity between Der p 5 and Der p 21 and Blo t 5 and Blo t 21, respectively [34, 43]. Additionally, some cross‐reactivity between Blo t 2 and Der p 2 has been reported [6]. However, the sequence identity between Blo t 10 and Der p 10 was very high (i.e., 94.37%) (Figure S2).
3.4. Group 1 Patients but Not Group 2 Patients Show IgE Reactivity to Blo t Extract
In a first pilot experiment, we investigated IgE reactivity to Blo t and Der p extracts in HDM‐sensitised patients from Blo t‐endemic regions (Group 1) and in HDM‐sensitised patients from Blo t‐non‐endemic regions (Group 2) (Figure 2). We found that Group 2 patients showed IgE reactivity to Der p extract but not to Blo t extract. Conversely, HDM‐sensitised patients from Blo t‐endemic regions showed IgE reactivity to Der p and Blo t extracts. No IgE binding to Blo t and Der p extracts was observed when serum from a non‐allergic subject or only buffer was tested (Figure 2).
FIGURE 2.

IgE reactivity (y‐axis: OD levels corresponding to bound IgE antibodies) of HDM‐sensitised patients from Blo t‐endemic (Group 1: #2, #4, #12, #13, #14, #16, #23, #24), Blo t‐non‐endemic regions (Group 2: 116, 117, 127, 128, 129) and of a non‐allergic subject (N) or buffer without serum (B) (x‐axis). The cut‐off value of 0.047 is indicated by a horizontal dashed line.
3.5. Microarray Containing Purified Blo t and Der p Allergens for Measuring Specific IgE and IgG Antibodies
In order to create a microarray containing both, Blo t and Der p allergen molecules, we expressed and purified a panel of recombinant Blomia tropicalis allergens including Blo t 2, Blo t 5, Blo t 8, Blo t 10, Blo t 12, Blo t 13 and Blo t 21 and combined them with earlier described Dermatophagoides allergen molecules on one microarray [26, 28, 37, 38, 39, 40, 41, 42, 43].
rBlo t 2 migrated at approximately 14.5 kDa, rBlo t 5 at 14 kDa, rBlo t 8 at 28 kDa, rBlo t 10 at 37 kDa, rBlo t 13 at 15 kDa and rBlo t 21 at 14 kDa (Figure S3A). As described earlier, rBlo t 12 seemed to form a dimer with a band of approximately 25 kDa instead of the expected 30 kDa which may be due to its acidic isoelectric point of 5.8. The dimer formation was observed earlier and may be explained by hydrophobic interactions [32]. According to the sequences of the recombinant allergens, the following molecular masses were calculated for the proteins with N‐terminal methionine: rBlo t 2: 14,471 Da; rBlo t 5: 14,845 Da; rBlo t 8: 28,405 Da; rBlo t 10: 33,853 Da; rBlo t 12: 15,161 Da; rBlo t 13: 15,622 Da; rBlo t 21: 14,195 Da. The calculated molecular masses were in reasonable agreement with those determined by mass spectrometry for the following allergens (Figure S3B): rBlo t 2: 14,594 Da; rBlo t 5: 15,212 Da; rBlo t 8: 28,813 Da; rBlo t 12: 15,358 Da; rBlo t 13: 15,617 Da; rBlo t 21: 14,312 Da. For rBlo t 10, the measured molecular mass was 34,673 Da which was bigger than the predicted molecular masses which may be attributed to the limitations of the precision of our instrument (Figure S3B).
Blo t 2 yielded a CD spectrum with a broad minimum between 210 and 215 nm, indicating a dominantly β‐sheet secondary structure. This is consistent with the AlphaFold2 structure prediction of Blo t 2, which showed a β‐barrel structure typical of a NPC2 family protein (PDB: 1KTJ) (Figure S3C).
The CD spectra of Blo t 5, Blo t 10 and Blo t 21 exhibited distinct minima at 208 and 222 nm indicative of a mainly α‐fold secondary structure. This corresponds well with the available experimental structures (PDB 2JMW and PDB 2LM, respectively [30, 34]) and with the AlphaFold2 prediction of Blo t 10, which is a tropomyosin (PDB: 1C1G). The three allergens are purely α‐helical proteins in their folded form.
Blo t 8 is a Glutathione S‐transferase with a mixed α/β‐fold as seen in the crystal structure (PDB 4Q5N) where it forms a homo‐dimer (PDB: 4Q5N; [31]). The CD spectrum of Blo t 8 exhibits a pronounced minimum at 222 nm and a lesser minimum at 208 nm, consistent with the experimental structure.
Blo t 12 contains a peritrophin‐like protein domain featuring a small globular C‐terminal domain with 2 or 3 β‐sheets and a mainly unstructured N‐terminal domain (PDB: AF_AFQ17282F1). The protein yields a CD spectrum with a distinct minimum at 200 nm indicative of an unfolded protein in solution. It should be noted that the natively folded structure is stabilised by two disulfide bonds and that the fold might be compromised by incorrect disulfide bond formation in the heterologous expression system.
The CD‐spectrum of Blo t 13 exhibits a broad minimum at 215 nm indicating a mainly β‐sheet containing protein (PDB: 8WKH; [33]). This is consistent with the crystal structure of Blo t 13 (PDB 8WKH), which yields a β‐barrel structure with a 10‐stranded antiparallel β‐sheet and 2 α‐helices capping the opening of the barrel.
Figure S4 shows the outlay of the microarray containing the aforementioned Der p and Blo t allergens which had been spotted in triplicates. The microarray contains the following HDM allergens: nDer p 1, nDer p 2, rDer p 4, rDer p 5, rDer p 7, rDer p 8, rDer p 10, rDer p 18, rDer p 20, rDer f 20, rDer p 21, rDer p 23, Der p 29 and rDer p 37 as well as the following Blo t allergens: Blo t 2, Blo t 5, Blo t 8, Blo t 10, Blo t 12, Blo t 13 and Blo t 21.
3.6. Microarray‐Based Discrimination of IgE Sensitisation to Blo t and Der p by Measuring IgE Levels Specific for Blo t and Der p Allergen Molecules
In a next step, we tested sera from group 1 and group 2 for IgE reactivity with the microarrayed allergens. IgE levels specific for Blo t 2, Blo t 5, Blo t 10, Blo t 12 and Blo t 21 were significantly higher in group 1 patients as compared to group 2 patients (Figure 3A). Table 2 shows that 78% of the group 1 patients were positive for Blo t 5, 60% reacted with Blo t 21 and 49% with Blo t 2 (Tables 2 and S3). Interestingly, 15% of group 2 patients showed IgE reactivity to Blo t 2, 21% to Blo t 5 and 18% to Blo t 21 (Tables 2 and S4). When comparing the group 1 patients with the group 2 patients in Figure 3B, we found that IgE levels specific for Der p 2, Der p 18 and Der p 21 were significantly higher in group 2 patients as compared to group 1 patients. The frequencies of IgE reactivity to Der p 1 in the group 1 patients were 74% and in group 2 patients 87% (Table 3). For Der p 2, frequencies of IgE recognition were 69% (group 1 patients) and 93% (group 2 patients). Results for Der p 5 were (46%, 84%), for Der p 21 (55%, 78%) and for Der p 23 (75%, 87%) for the previously mentioned group 1 and group 2 patients (Table 3). Thus, certain Dermatophagoides allergens were more frequently recognised by group 2 patients than by group 1 patients.
FIGURE 3.

IgE reactivity (y‐axes: ISU corresponding to IgE levels) of HDM‐sensitised patients from Blo t‐endemic (full dots, left) and Blo t‐non‐endemic regions (open circles, right) to Blomia tropicalis allergens (A) and HDM allergens (B) (x‐axes). Horizontal red bars indicate the median values, significant differences between patients are indicated (*p < 0.05, **p < 0.01, ***p < 0.001, Mann–Whitney U test). The horizontal dashed lines denote the cut‐off level of 0.3 ISU.
TABLE 2.
Frequencies of IgE recognition and IgE levels specific for individual Blo t allergens (Blo t 2, Blo t 5, Blo t 21) and the sums of the aforementioned Blomia tropicalis allergens in HDM‐sensitised patients from Blo t‐endemic and Blo t‐non‐endemic regions.
| Group 1 (n = 115) | Group 2 (n = 33) | ||||
|---|---|---|---|---|---|
| Blo t 2 | Blo t 2 | ||||
| Range (ISU) | Median | % of positive patients | Range (ISU) | Median | % of positive patients |
| 0.46–50.61 | 1.87 | 48.50% | 0.49–18.33 | 0.73 | 15.00% |
| Blo t 5 | Blo t 5 | ||||
| Range (ISU) | Median | % of positive patients | Range (ISU) | Median | % of positive patients |
| 0.36–298.06 | 8.89 | 77.90% | 0.66–10.61 | 1.01 | 21.00% |
| Blo t 21 | Blo t 21 | ||||
| Range (ISU) | Median | % of positive patients | Range (ISU) | Median | % of positive patients |
| 0.31–291.55 | 38.85 | 60.20% | 0.41–31.30 | 1.69 | 18.00% |
| ∑ (Positive to Blo t 2, 5, 21) | Percentage positive | ∑ (Positive to Blo t 2, 5, 21) | Percentage positive | ||
| n = 68 | 59.10% | n = 9 | 36.00% | ||
TABLE 3.
Frequencies of IgE recognition and IgE levels specific for individual Der p allergens (Der p 1, Der p 2, Der p 5, Der p 21, Der p 23) and the sums of the aforementioned Dermatophagoides allergens in HDM‐sensitised patients from Blo t‐endemic and Blo t‐non‐endemic regions.
| Group 1 (n = 115) | Group 2 (n = 33) | ||||
|---|---|---|---|---|---|
| Der p 1 | Der p 1 | ||||
| Range (ISU) | Median | % of positive patients | Range (ISU) | Median | % of positive patients |
| 0.36–134.18 | 39.93 | 74.10% | 1.50–197.89 | 46.83 | 87.00% |
| Der p 2 | Der p 2 | ||||
| Range (ISU) | Median | % of positive patients | Range (ISU) | Median | % of positive patients |
| 0.41–122.90 | 31.21 | 69.40% | 8.97–292.21 | 85.81 | 93.00% |
| Der p 5 | Der p 5 | ||||
| Range (ISU) | Median | % of positive patients | Range (ISU) | Median | % of positive patients |
| 0.51–119.11 | 25.39 | 45.50% | 0.41–218.75 | 27.96 | 84.00% |
| Der p 21 | Der p 21 | ||||
| Range (ISU) | Median | % of positive patients | Range (ISU) | Median | % of positive patients |
| 0.36–142.15 | 15.33 | 55.30% | 0.73–137.74 | 29.06 | 78.00% |
| Der p 23 | Der p 23 | ||||
| Range (ISU) | Median | % of positive patients | Range (ISU) | Median | % of positive patients |
| 0.32–142.21 | 17.36 | 75% | 0.61–287.45 | 46.28 | 87% |
| ∑ (positive to Der p 1, 2, 5, 21, 23) | Percentage positive | ∑ (positive to Der p 1, 2, 5, 21, 23) | Percentage positive | ||
| n = 112 | 97.30% | n = 33 | 100.00% | ||
3.7. Detailed Examples for Microarray‐Based Discrimination of IgE Sensitisation to Blo t and Der p
When analysing individual patients from group 1 and group 2, we found patients with distinct sensitisation profiles to Blo t and Der p allergens. For example, patient #1 (Table S3) seems to be exclusively sensitised to Blomia with the following sensitisation profile: specific IgE levels for Der p 1: 0 ISU, Der p 2: 0 ISU, Der p 5: 0 ISU, Der p 10: 0 ISU, Der p 21: 0 ISU, Der p 23: 0 ISU, Blo t 2: 0 ISU, Blo t 5: 4.30 ISU, Blo t 10: 0 ISU, Blo t 21: 36.85 ISU. Patient #5 (Table S3) seems to be genuinely Blomia sensitised and showed cross‐reactivity to Dermatophagoides allergens. Specific IgE sensitisation profile and levels for Der p 1: 0 ISU, Der p 2: 0 ISU, Der p 5: 1.43 ISU, Der p 10: < 0.3 ISU, Der p 21: 142.15 ISU, Der p 23: 0 ISU, Blo t 2: 0 ISU, Blo t 5: 298.05 ISU, Blo t 10: 0 ISU, Blo t 21: 291.55 ISU. Patient #119 (Table S4) was exclusively sensitised to Dermatophagoides with the following IgE reactivity profile: specific IgE levels for Der p 1: 24.01 ISU, Der p 2: 45.94 ISU, Der p 5: 0 ISU, Der p 10: 0 ISU, Der p 21: 0 ISU, Der p 23: 0 ISU, Blo t 2: 0 ISU, Blo t 5: 0 ISU, Blo t 10: 0 ISU, Blo t 21: 0 ISU. Patient #123 (Table S4) was sensitised to Dermatophagoides and showed cross‐reactivity to Blomia exhibiting the following IgE reactivity profile: Der p 1: 58.64 ISU, Der p 2: 92.93 ISU, Der p 5: 12.07 ISU, Der p 10: 0 ISU, Der p 21: 84.48 ISU, Der p 23: 59.44 ISU, Blo t 2: 0 ISU, Blo t 5: < 0.3 ISU, Blo t 10: 0 ISU, Blo t 21: 10.34 ISU. Finally, patient #9 (Table S3) was a patient with co‐sensitisation to Blomia and Dermatophagoides. The profile was: Der p 1: 0 ISU, Der p 2: 15.38 ISU, Der p 5: 0 ISU, Der p 10: 0 ISU, Der p 21: < 0.3 ISU, Der p 23: 0 ISU, Blo t 2: 2.07 ISU, Blo t 5: 124.46 ISU, Blo t 10: 0 ISU, Blo t 21: 51.46 ISU.
3.8. IgG Reactivity to Certain Recombinant Blo t Allergens Is Significantly Higher in HDM‐Sensitised Patients From Blo t‐Endemic Regions Than in HDM‐Sensitised Patients From Blo t‐Non‐Endemic Regions
A comparison of the IgG levels to Blomia allergens (Figure S5A, Table S5) and to Dermatophagoides allergens (Figure S5B, Table S6) is shown for group 1 patients and group 2 patients. IgG levels specific for Blo t 2, Blo t 8, Blo t 12, Blo t 13 and Blo t 21 were significantly higher in HDM‐sensitised patients from Blo t‐endemic regions as compared to HDM‐sensitised patients from Blo t‐non‐endemic regions (Figure S5A). Conversely, IgG levels to Der p 10 were significantly higher in group 2 patients as compared to group 1 patients. Interestingly, IgG levels to Der p 5, Der p 7, Der p 8, Der p 18, Der p 20, Der p 23 and Der p 37 were significantly higher in group 1 patients than in group 2 patients.
3.9. Discrimination of Genuine IgE Sensitisation to Blo t and Der p May Be Refined by Considering Molecular IgE Reactivity Profiles, Allergen‐Specific IgE Levels and IgE Inhibition
Besides determining IgE reactivity profiles and measuring allergen specific IgE levels to microarrayed Blo t and Der p allergens, we also investigated if inhibition of IgE binding by pre‐incubation of patients' sera with defined allergens can be useful for the discrimination of genuine IgE sensitisation to Blo t and Der p. Examples are presented in Figure 4. Figure 4A presents an example of a patient with co‐sensitisation to Blo t and Der p. Although IgE binding to Blo t 2, Blo t 5, Blo t 21, Der p 2, Der p 5 and Der p 21 was completely inhibited by the mix of the three Blo t allergens, this patient showed high IgE reactivity to Der p 23 (Table S3). IgE binding of patient 9 (Figure 4B) to Blo t 5 and Blo t 21 was higher than IgE binding to the homologous Der p allergens (Der p 5, Der p 21) and could not be inhibited by the Der p allergen mix. However, IgE reactivity to Der p 2 was higher than to Blo t 2 and was only partly inhibited with the Blo t mix (Figure 4B, Table S3). Patients 11, 8, 10, 12, 13 and 14 from the Blo t‐endemic region also appeared co‐sensitised to Blo t and Der p because their IgE levels to at least one of the Blo t or Der p allergens were higher than to the corresponding allergens in the other species (Figure 4C–H). Der p sensitisation in patient 12 was also supported by IgE reactivity to Der p 1 and Der p 23 (Table S3). However, we found patients with exclusive and genuine Blo t sensitisation with exclusive IgE reactivity only to Blo t allergens or higher IgE reactivity to Blo t allergens than the corresponding Der p allergens (e.g., patient 113, 1) (Table S3). Genuine Der p sensitisation was found for patient 126 whose IgE levels to Der p allergens were higher than to Blo t allergens and IgE inhibition to Blo t allergens was complete by the Der p allergen mix (Figure 4I). Patients 124 and 137 reacted only with Der p allergens although a partial inhibition of IgE binding to certain Der p allergens was found with the Blo t allergen mix (Figure 4K,L; Table S4). The latter three patients were from the Blo t‐non‐endemic region. Interestingly, patient 128 from the Blo t‐non‐endemic region appeared co‐sensitised because IgE levels to Blo t 21 were higher than to Der p 21 and the inhibition of IgE binding to Blo t 21 by the Der p mix was incomplete (Figure 4J). When taking into account the results of molecular IgE reactivity profiles and allergen‐specific IgE levels and IgE inhibition results it seemed that molecular IgE reactivity profiles and allergen‐specific IgE levels may be sufficient for the discrimination of genuine sensitisation to Blo t, Der p and co‐sensitisation. Figure 5 suggests a preliminary algorithm for this differential diagnosis of IgE sensitisation with the allergen molecules present on our current microarray. When IgE levels to each of the indicated Blo t allergens are higher than to the homologous Der p allergens and there is no IgE reactivity to Der p 1, Der p 7 and Der p 23 we suspect genuine Blo t sensitisation (Figure 5). Genuine Der p sensitisation is likely when IgE levels to the indicated Der p allergens are higher than to the corresponding Blo t allergens with or without sensitisation to Der p 1, Der p 7 or Der p 23 (Figure 5). Co‐sensitisation to Blo t and Der p is likely when IgE levels to at least one of the indicated Blo t or Der p allergens are higher than to the corresponding allergen from the other allergen source regardless if Der p 1, Der p 7 or Der p 23 is positive.
FIGURE 4.

IgE reactivity of HDM‐sensitised patients from Blo t‐endemic regions (Group 1) (A) (#2, #9, #11, #8, #10, #12, #13, #14) or HDM‐sensitised patients from Blo t‐non‐endemic regions (Group 2) (B) (#126, #128, #124, #137) to microarrayed Blomia tropicalis (Blo t 2, Blo t 5, Blo t 21) and Der p allergens (Der p 2, Der p 5, Der p 21) after preadsorption of sera with a mix of Blo t allergens (BT: Blo t 2, Blo t 5, Blo t 21), Der p allergens (DP: Der p 2, Der p 5, Der p 21) or an unrelated control allergen (CT: Bet v 1). Y‐axes show specific IgE levels (ISU).
FIGURE 5.

Algorithm for molecular allergy diagnosis of IgE sensitisation to Blomia tropicalis and Dermatophagoides revealing different forms of IgE sensitisation and possible recommendations for AIT based on qualitative IgE reactivity profiles and allergen‐specific IgE levels.
4. Discussion
The differential diagnosis of IgE sensitisation to Dermatophagoides and Blomia tropicalis is of high importance in subtropical and tropical regions where both mite species frequently co‐occur [47, 48]. While there is almost complete IgE cross‐reactivity between allergens from mites within the genus Dermatophagoides, IgE cross‐reactivity between allergens from Dermatophagoides and Blomia is limited [3, 49]. In order to identify patients for Dermatophagoides and/or Blomia‐specific AIT in patients exposed to both mite genera, it is important to discriminate between genuine sensitisation to Blomia tropicalis, genuine sensitisation to Dermatophagoides and co‐sensitisation to both genera. The goal of our study was to facilitate the discrimination of genuine IgE sensitisation to Der p and Blo t. For this purpose, we have developed an allergen microarray containing a panel of seven Blo t and thirteen Der p allergen molecules and evaluated this microarray by testing sera from HDM sensitised patients from Blo t‐endemic (group 1) or Blo t‐non‐endemic regions (group 2).
The microarray based on Blo t and Der p allergen molecules for the discrimination of IgE sensitisation to Blo t and Der p is based on the comparison of IgE levels to the individual allergen molecules which is possible because frequently recognised key allergen molecules in Blomia (e.g., Blo t 2, Blo t 5 and Blo t 21) differ considerably from related allergens in Dermatophagoides (i.e., Der p 2, Der p 5 and Der p 21) in terms of sequence homology and IgE‐cross‐reactivity (Figure S2). Accordingly, we found that group 1 showed significantly higher IgE levels to Blo t 2, Blo t 5 and Blo t 21 than group 2 while Der p 2 and Der p 21‐specific IgE levels in group 2 patients were significantly higher than in group 1. IgG levels to most of the Blo t allergens were significantly higher in group 1 as compared to group 2, confirming the Blo t exposure of group 1 patients, whereas both groups, group 1 and group 2, showed variable IgG responses to Der p allergens indicating that both populations are exposed to Der p.
We further studied detailed molecular IgE recognition profiles of patients as exemplified in Tables S3 and S4. This detailed analysis showed that based on IgE reactivity patterns and allergen‐specific IgE levels, patients can be categorised into patients with a genuine sensitisation to Blo t, a genuine IgE sensitisation to Der p or a co‐sensitisation to Blo t and Der p (Figure 5). The advantage of molecular testing over allergen extract‐based testing becomes obvious if one compares allergen extract‐based testing as done for patients 13, 16 and 23, where IgE levels to Der p extract were much higher than those to Blo t extract, suggesting that Der p might be the genuinely sensitising allergen source (Figure 2). However, molecular testing demonstrated that each of the three patients had also a Blo t co‐sensitisation. Another surprising example is patient #12, who had much higher IgE levels to Blo t extract than to Der p extract, but by molecular diagnosis turned out to be co‐sensitised to Blo t and Der p. How can such discrepancies between allergen extract‐based testing and molecular diagnosis be explained? In fact, it has been shown that Der p allergen extracts vary strongly regarding contents of individual allergens, with certain important allergens (e.g., Der p 5, Der p 21 and Der p 23) being under‐represented [50]. The experiment shown in Figure 1 confirms this earlier observation because no or low amounts of Der p 5 and Der p 21, respectively, were detected in the Der p allergen extract. Interestingly, the anti‐Der p 21 antibodies reacted even stronger with Blo t extract than with Der p extract. Furthermore, amounts of Blo t 5 and Blo t 21 seemed to be low in Blo t extracts. It is thus obvious that allergen extract‐based diagnosis for Der p and Blo t sensitisation has limitations which can only be overcome by molecular testing.
We further demonstrate that molecular testing for detecting Blo t and Der p sensitisation can be confirmed by microarray‐based IgE inhibition experiments as shown in Figure 4. For this purpose, sera were pre‐incubated with purified Blo t or Der p allergens to investigate against what allergens the majority of specific IgE antibodies are directed.
Our data indicate that Blo t 2, Blo t 5 and Blo t 21 as well as Der p 2, Der p 5 and Der p 21 may be sufficient for the differential diagnosis of IgE sensitisation of Blo t and Der p. However, we think that the addition of additional allergens to the microarray such as Blo t 1 vs. Der p 1, Blo t 7 vs. Der p 7, Blo t 13 vs. Der p 13 and Blo t 23 vs. Der p 23 will increase the sensitivity and specificity of the differential diagnostics approach. Towards this goal we have produced recombinant Blo t 1 in HEK cells based on the sequence described in Genbank: AAQ24541 as secreted and soluble protein. However, the recombinant Blo t 1 fusion protein showed no IgE reactivity with any of the sera in our study (data not shown) although the recombinant allergen was in principle functional because it reacted with serum IgE from highly Der p 1 sensitised patients (data not shown). One possible reason why Blo t 1 based on the sequence described in Genbank: AAQ24541 did not react well with IgE from patients from Blo t 1‐endemic regions is that this particular isoform is less IgE‐reactive than other described sequences such as (GenBank: OQ285922.1 or GenBank: WBV73456.1 and: https://www.biorxiv.org/content/10.1101/2023.02.09.527948v1.full). It will therefore be necessary to study the IgE reactivity of different Blo t 1 isoallergens which is beyond the scope of our paper.
Nevertheless, the microarray presented in our work represents an important step towards the identification of patients with genuine sensitisation towards Blo t and Der p and will be useful for improving the prescription of Blo t and Dermatophagoides‐specific AIT. Measurement of the development of allergen‐specific IgG antibodies in the course of AIT and the decline of allergen‐specific IgE signals due to competing IgG antibodies [51, 52] will additionally assist to evaluate the development of allergen‐specific IgG antibodies which are important biomarkers for the effect of AIT. At minimum, our microarray will be helpful in understanding disease aetiology and be useful for fine resolution mapping of allergic reactivity in HDM sensitisation.
Author Contributions
N.D., S.V. and R.V. contributed to the design of the study, interpreted the findings and wrote the manuscript. S.V. and R.V. designed the study and contributed to the interpretation of the findings, writing and revising the manuscript. N.D., S.P., P.Z., M.W., E.S., G.P., H.‐J.H., M.F.‐T., M.T., W.K., T.S., L.C., A.T., P.T., R.V. and S.V. provided materials, read and revised the manuscript. All authors contributed to the article and approved the submitted version.
Funding
This study was funded by the Danube Allergy Research Cluster, Country of Lower Austria and in part by Grant No. 23‐75‐30016 from the Russian Science Foundation in its part related to allergen preparation and characterisation. This study was also supported by the Austrian Science Fund (FWF) doc.funds Biomolecular Structures and Interactions (DOC 130) and by the Health Systems Research Institute (HSRI: 68‐039).
Conflicts of Interest
Rudolf Valenta has received research grants from HVD Life Science, Vienna Austria and from WORG Pharmaceuticals, Hangzhou, China and serves as a consultant for WORG and Viravaxx. The authors with a Russian affiliation declare that they have prepared the article in their ‘personal capacity’ and/or that they are employed at an academic/research institution where research or education is the primary function of the entity. The other authors have no conflicts of interest to report.
Supporting information
FIGURE S1: Coomassie Brilliant Blue‐stained SDS‐PAGE containing different amounts (Lanes: 5, 10, 15, 20 μg) of Blomia tropicalis (Blo t), Dermatophagoides (Der p) protein extracts and a molecular weight marker (Lane M). Molecular weights (kDa) are indicated on the left margin.
FIGURE S2: Alignments of the amino acids sequences of Blo t 2 (GenBank: AAQ73483.1) and Der p 2 (GenBank: AAF86462.1) (A), Blo t 5 (GenBank: AAD10850.1) and Der p 5 (GenBank: AAB32842.1) (B), Blo t 8 (GenBank: ACV04860.1) and Der p 8 (GenBank: AAB32224.1) (C), Blo t 10 (GenBank: ABU97466.1) and Der p 10 (GenBank: CAA75141.1) (D), and Blo t 21 (GenBank: AAX34047.1) and Der p 21 (GenBank: ABC73706.1) (E). Identical amino acids are indicated by dashes, gaps by dots and different amino acids by colours (red: acidic hydrophilic; yellow: neutral; green: basic hydrophilic; blue: hydrophobic). Numbers of amino acids are displayed on the right margin.
FIGURE S3: Coomassie Brilliant Blue‐stained SDS‐PAGE (A) containing purified recombinant B. tropicalis allergens (Lanes: Blo t 2, Blo t 5, Blo t 8, Blo t 10, Blo t 12, Blo t 13, Blo t 21). Molecular weights (kDa) are indicated on the left margin (M). Mass Spectrometry (MALDI) analysis of recombinant Blo t allergens (Blo t 2, Blo t 5, Blo t 8, Blo t 10, Blo t 12, Blo t 13, Blo t 21) (B). X‐axes show molecular masses (Dalton) and y‐axes signal intensities. Circular Dichroism analysis of the aforementioned Blo t allergens (C). Mean residue ellipticities (y‐axes) are shown for different wavelengths (x‐axes).
FIGURE S4: Outlay of the allergen microarray. Indicated are guide dot triplicates (empty circles, top) and positions of the spotted allergen triplicates.
FIGURE S5: IgG reactivity (y‐axis: ISU IgG corresponding to IgG levels) of HDM‐sensitised patients from Blo t endemic (full dots, left) and Blo t‐non‐endemic regions (open circles, right) to Blomia tropicalis allergens (A) and Dermatophagoides allergens (B) (x‐axes). Horizontal red bars indicate the median values whereas the dashed horizontal lines indicade the cut‐offs. Significant differences between patients are indicated (*p < 0.05, **p < 0.01, ***p < 0.001, Mann–Whitney U test).
TABLE S1: Demographic and clinical characterisation of HDM‐sensitised patients from Blo t‐endemic regions.
TABLE S2: Demographic and clinical characterisation of HDM‐sensitised patients from Blo t‐non‐endemic regions.
TABLE S3: Heat map of IgE reactivity of HDM‐sensitised patients from Blo t‐endemic regions (#1–115) to Blomia tropicalis and Dermatophagoides pteronyssinus allergens (Der p 1, Blo t 2, Der p 2, Der p 4, Blo t 5, Der p 5, Der p 7, Blo t 8, Der p 8, Blo t 10, Der p 10, Blo t 12, Blo t 13, Der p 18, Der p 20, Blo t 21, Der p 21, Der p 23, Der p 29, Der p 37). Colour codes for IgE levels are indicated at the bottom of the table. ISU, international standardised unit; ND, not done.
TABLE S4: Heat map of IgE reactivity of HDM‐sensitised patients from Blo t‐non‐endemic regions (#116–148) to Blomia tropicalis and Dermatophagoides pteronyssinus allergens (Der p 1, Blo t 2, Der p 2, Der p 4, Blo t 5, Der p 5, Der p 7, Blo t 8, Der p 8, Blo t 10, Der p 10, Blo t12, Blo t 13, Der p 18, Der p 20, Blo t 21, Der p 21, Der p 23, Der p 29, Der p 37). Colour codes for IgE levels are indicated at the bottom of the table. ISU, international standardised unit; ND, not done.
TABLE S5: Heat map of IgG reactivity of HDM‐sensitised patients from Blo t‐endemic regions (#1–115) to Blomia tropicalis and Dermatophagoides pteronyssinus allergens (Der p 1, Blo t 2, Der p 2, Der p 4, Blo t 5, Der p 5, Der p 7, Blo t 8, Der p 8, Blo t 10, Der p 10, Blo t12, Blo t 13, Der p 18, Der p 20, Blo t 21, Der p 21, Der p 23, Der p 29, Der p 37).). Colour codes for IgG levels are indicated at the bottom of the table. ISU IgG, international standardised unit; ND, not done.
TABLE S6: Heat map of IgG reactivity of HDM‐sensitised patients from Blo t‐non‐endemic regions (#116–148) to Blomia tropicalis and Dermatophagoides pteronyssinus allergens (Der p 1, Blo t 2, Der p 2, Der p 4, Blo t 5, Der p 5, Der p 7, Blo t 8, Der p 8, Blo t 10, Der p 10, Blo t12, Blo t 13, Der p 18, Der p 20, Blo t 21, Der p 21, Der p 23, Der p 29, Der p 37). Colour codes for IgG levels are indicated at the bottom of the table. ISU IgG, international standardised unit; ND, not done.
Acknowledgements
Open Access funding provided by Medizinische Universitat Wien/KEMÖ.
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
- 1. Boulet L. P., Turcotte H., Laprise C., et al., “Comparative Degree and Type of Sensitization to Common Indoor and Outdoor Allergens in Subjects With Allergic Rhinitis and/or Asthma,” Clinical and Experimental Allergy 27, no. 1 (1997): 52–59. [PubMed] [Google Scholar]
- 2. Arlian L. G., Bernstein D., Bernstein I. L., et al., “Prevalence of Dust Mites in the Homes of People With Asthma Living in Eight Different Geographic Areas of the United States,” Journal of Allergy and Clinical Immunology 90, no. 3 Pt 1 (1992): 292–300, 10.1016/s0091-6749(05)80006-5. [DOI] [PubMed] [Google Scholar]
- 3. Caraballo L., Lockey R., Puerta L., Zakzuk J., Acevedo N., and Fernández‐Caldas E., “ Blomia tropicalis: A 50‐Year History,” Journal of Allergy and Clinical Immunology in Practice (2024), 10.1016/j.jaip.2024.11.007. [DOI] [PubMed] [Google Scholar]
- 4. Fernández‐Caldas E., Fox R. W., Bucholtz G. A., Trudeau W. L., Ledford D. K., and Lockey R. F., “House Dust Mite Allergy in Florida. Mite Survey in Households of Mite‐Sensitive Individuals in Tampa, Florida,” Allergy Proceedings 11, no. 6 (1990): 263–267, 10.2500/108854190778879710. [DOI] [PubMed] [Google Scholar]
- 5. Puerta L., Fernández‐Caldas E., Lockey R. F., et al., “Mite Allergy in the Tropics: Sensitization to Six Domestic Mite Species in Cartagena, Colombia,” Journal of Investigational Allergology & Clinical Immunology 3, no. 4 (1993): 198–204. [PubMed] [Google Scholar]
- 6. Pauli G., Wurmser C., Roos A., et al., “Frequent IgE Recognition of Blomia tropicalis Allergen Molecules in Asthmatic Children and Young Adults in Equatorial Africa,” Frontiers in Immunology 14 (2023): 1133935, 10.3389/fimmu.2023.1133935. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Kwizera R., Wadda V., Mugenyi L., et al., “Skin Prick Reactivity Among Asthmatics in East Africa,” World Allergy Organization Journal 13, no. 6 (2020): 100130, 10.1016/j.waojou.2020.100130. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Trakultivakorn M., “Prevalence of Asthma, Rhinitis, and Eczema in Northern Thai Children From Chiang Mai (International Study of Asthma and Allergies in Childhood, ISAAC),” Asian Pacific Journal of Allergy and Immunology 17, no. 4 (1999): 243–248. [PubMed] [Google Scholar]
- 9. Daengsuwan T., Lee B. W., Visitsuntorn N., et al., “Allergen Sensitization to Aeroallergens Including Blomia tropicalis Among Adult and Childhood Asthmatics in Thailand,” Asian Pacific Journal of Allergy and Immunology 21, no. 4 (2003): 199–204. [PubMed] [Google Scholar]
- 10. Yeoh S. M., Kuo I. C., Wang D. Y., et al., “Sensitization Profiles of Malaysian and Singaporean Subjects to Allergens From Dermatophagoides pteronyssinus and Blomia tropicalis ,” International Archives of Allergy and Immunology 132, no. 3 (2003): 215–220, 10.1159/000074302. [DOI] [PubMed] [Google Scholar]
- 11. Kuo I. C., Yi F. C., Cheong N., et al., “Sensitization to Blomia tropicalis and Dermatophagoides pteronyssinus—A Comparative Study Between Singapore and Taiwan,” Asian Pacific Journal of Allergy and Immunology 17, no. 3 (1999): 179–188. [PubMed] [Google Scholar]
- 12. Luo W., Hu H., Tang W., et al., “Allergen Sensitization Pattern of Allergic Adults and Children in Southern China: A Survey Based on Real Life Data,” Allergy, Asthma and Clinical Immunology 15 (2019): 42, 10.1186/s13223-019-0357-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Mourao E. M. M. and Rosario N. A., “Conjunctival Provocation Test With Blomia tropicalis ,” Frontiers in Allergy 2 (2021): 673462, 10.3389/falgy.2021.673462. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Stanaland B. E., Fernández‐Caldas E., Jacinto C. M., Trudeau W. L., and Lockey R. F., “Positive Nasal Challenge Responses to Blomia tropicalis ,” Journal of Allergy and Clinical Immunology 97, no. 5 (1996): 1045–1049, 10.1016/s0091-6749(96)70256-7. [DOI] [PubMed] [Google Scholar]
- 15. Simpson A., Green R., Custovic A., Woodcock A., Arruda L. K., and Chapman M. D., “Skin Test Reactivity to Natural and Recombinant Blomia and Dermatophagoides spp. Allergens Among Mite Allergic Patients in the UK,” Allergy 58, no. 1 (2003): 53–56, 10.1034/j.1398-9995.2003.23354.x. [DOI] [PubMed] [Google Scholar]
- 16. Kiewiet M. B. G., Lupinek C., Vrtala S., et al., “A Molecular Sensitization Map of European Children Reveals Exposome‐ and Climate‐Dependent Sensitization Profiles,” Allergy 78, no. 7 (2023): 2007–2018, 10.1111/all.15689. [DOI] [PubMed] [Google Scholar]
- 17. Santos da Silva E., Asam C., Lackner P., et al., “Allergens of Blomia tropicalis: An Overview of Recombinant Molecules,” International Archives of Allergy and Immunology 172, no. 4 (2017): 203–214, 10.1159/000464325. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Reginald K., Pang S. L., and Chew F. T., “Blo t 2: Group 2 Allergen From the Dust Mite Blomia tropicalis ,” Scientific Reports 9, no. 1 (2019): 12239, 10.1038/s41598-019-48688-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Lahiani S., Dumez M. E., Khemili S., Bitam I., Gilis D., and Galleni M., “Cross‐Reactivity Between Major IgE Epitopes of Family 5 Allergens From Dermatophagoides pteronyssinus and Blomia tropicalis ,” International Archives of Allergy and Immunology 178, no. 1 (2019): 10–18, 10.1159/000492871. [DOI] [PubMed] [Google Scholar]
- 20. Kuo I. C., Cheong N., Trakultivakorn M., Lee B. W., and Chua K. Y., “An Extensive Study of Human IgE Cross‐Reactivity of Blo t 5 and Der p 5,” Journal of Allergy and Clinical Immunology 111, no. 3 (2003): 603–609, 10.1067/mai.2003.167. [DOI] [PubMed] [Google Scholar]
- 21. Tan K. W., Ong T. C., Gao Y. F., et al., “NMR Structure and IgE Epitopes of Blo t 21, a Major Dust Mite Allergen From Blomia tropicalis ,” Journal of Biological Chemistry 287, no. 41 (2012): 34776–34785, 10.1074/jbc.M112.348730. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. da Silva E. S., Aglas L., Pinheiro C. S., et al., “A Hybrid of Two Major Blomia tropicalis Allergens as an Allergy Vaccine Candidate,” Clinical and Experimental Allergy 50, no. 7 (2020): 835–847, 10.1111/cea.13611. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Castro‐Almarales R. L., Ronquillo‐Díaz M., Álvarez‐Castelló M., et al., “Subcutaneous Allergen Immunotherapy for Asthma: A Randomized, Double‐Blind, Placebo‐Controlled Study With a Standardized Blomia tropicalis Vaccine,” World Allergy Organization Journal 13, no. 4 (2020): 100098, 10.1016/j.waojou.2020.100098. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Chen K. W., Zieglmayer P., Zieglmayer R., et al., “Selection of House Dust Mite‐Allergic Patients by Molecular Diagnosis May Enhance Success of Specific Immunotherapy,” Journal of Allergy and Clinical Immunology 143, no. 3 (2019): 1248–1252.e12, 10.1016/j.jaci.2018.10.048. [DOI] [PubMed] [Google Scholar]
- 25. Chen K. W., Focke‐Tejkl M., Blatt K., et al., “Carrier‐Bound Nonallergenic Der p 2 Peptides Induce IgG Antibodies Blocking Allergen‐Induced Basophil Activation in Allergic Patients,” Allergy 67, no. 5 (2012): 609–621, 10.1111/j.1398-9995.2012.02794.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Curin M., Garmatiuk T., Resch‐Marat Y., et al., “Similar Localization of Conformational IgE Epitopes on the House Dust Mite Allergens Der p 5 and Der p 21 Despite Limited IgE Cross‐Reactivity,” Allergy 73, no. 8 (2018): 1653–1661, 10.1111/all.13398. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Gattinger P., Niespodziana K., Stiasny K., et al., “Neutralization of SARS‐CoV‐2 Requires Antibodies Against Conformational Receptor‐Binding Domain Epitopes,” Allergy 77, no. 1 (2022): 230–242, 10.1111/all.15066. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Sarzsinszky E., Lupinek C., Vrtala S., et al., “Expression in Escherichia Coli and Purification of Folded rDer p 20, the Arginine Kinase From Dermatophagoides pteronyssinus: A Possible Biomarker for Allergic Asthma,” Allergy, Asthma & Immunology Research 13, no. 1 (2021): 154–163, 10.4168/aair.2021.13.1.154. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Riabova K., Karsonova A. V., van Hage M., et al., “Molecular Allergen‐Specific IgE Recognition Profiles and Cumulative Specific IgE Levels Associated With Phenotypes of Cat Allergy,” International Journal of Molecular Sciences 23, no. 13 (2022): 6984, 10.3390/ijms23136984. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Chan S. L., Ong T. C., Gao Y. F., et al., “Nuclear Magnetic Resonance Structure and IgE Epitopes of Blo t 5, a Major Dust Mite Allergen,” Journal of Immunology 181, no. 4 (2008): 2586–2596, 10.4049/jimmunol.181.4.2586. [DOI] [PubMed] [Google Scholar]
- 31. Mueller G. A., Pedersen L. C., Glesner J., et al., “Analysis of Glutathione S‐Transferase Allergen Cross‐Reactivity in a North American Population: Relevance for Molecular Diagnosis,” Journal of Allergy and Clinical Immunology 136, no. 5 (2015): 1369–1377, 10.1016/j.jaci.2015.03.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. da Silva E. S., Pacheco L. G. C., Fernandes A. M. S., et al., “Purification and Characterisation of the Dimeric Group 12 Allergen From Blomia tropicalis Heterologously Expressed by Escherichia coli Top10F´,” Molecular Biology Reports 48, no. 4 (2021): 3405–3416, 10.1007/s11033-021-06361-6. [DOI] [PubMed] [Google Scholar]
- 33. Zhou Y., Zhu K., Li Q., et al., “Immunobiological Properties and Structure Analysis of Group 13 Allergen From Blomia tropicalis and Its IgE‐Mediated Cross‐Reactivity,” International Journal of Biological Macromolecules 254, no. Pt 3 (2024): 127788, 10.1016/j.ijbiomac.2023.127788. [DOI] [PubMed] [Google Scholar]
- 34. Gao Y. F., Wang de Y., Ong T. C., Tay S. L., Yap K. H., and Chew F. T., “Identification and Characterization of a Novel Allergen From Blomia tropicalis: Blo t 21,” Journal of Allergy and Clinical Immunology 120, no. 1 (2007): 105–112, 10.1016/j.jaci.2007.02.032. [DOI] [PubMed] [Google Scholar]
- 35. Jumper J., Evans R., Pritzel A., et al., “Highly Accurate Protein Structure Prediction With AlphaFold,” Nature 596, no. 7873 (2021): 583–589, 10.1038/s41586-021-03819-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Mirdita M., Schütze K., Moriwaki Y., Heo L., Ovchinnikov S., and Steinegger M., “ColabFold: Making Protein Folding Accessible to All,” Nature Methods 19, no. 6 (2022): 679–682, 10.1038/s41592-022-01488-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Huang H. J., Resch‐Marat Y., Casset A., et al., “IgE Recognition of the House Dust Mite Allergen Der p 37 Is Associated With Asthma,” Journal of Allergy and Clinical Immunology 149, no. 3 (2022): 1031–1043, 10.1016/j.jaci.2021.07.040. [DOI] [PubMed] [Google Scholar]
- 38. Weghofer M., Grote M., Resch Y., et al., “Identification of Der p 23, a Peritrophin‐Like Protein, as a New Major Dermatophagoides pteronyssinus Allergen Associated With the Peritrophic Matrix of Mite Fecal Pellets,” Journal of Immunology 190, no. 7 (2013): 3059–3067, 10.4049/jimmunol.1202288. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39. Curin M., Huang H. J., Garmatiuk T., et al., “IgE Epitopes of the House Dust Mite Allergen Der p 7 Are Mainly Discontinuous and Conformational,” Frontiers in Immunology 12 (2021): 687294, 10.3389/fimmu.2021.687294. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Resch Y., Weghofer M., Seiberler S., et al., “Molecular Characterization of Der p 10: A Diagnostic Marker for Broad Sensitization in House Dust Mite Allergy,” Clinical and Experimental Allergy 41, no. 10 (2011): 1468–1477, 10.1111/j.1365-2222.2011.03798.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Lupinek C., Wollmann E., Baar A., et al., “Advances in Allergen‐Microarray Technology for Diagnosis and Monitoring of Allergy: The MeDALL Allergen‐Chip,” Methods 66, no. 1 (2014): 106–119, 10.1016/j.ymeth.2013.10.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42. Resch Y., Blatt K., Malkus U., et al., “Molecular, Structural and Immunological Characterization of Der p 18, a Chitinase‐Like House Dust Mite Allergen,” PLoS One 11, no. 8 (2016): e0160641, 10.1371/journal.pone.0160641. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Weghofer M., Dall’Antonia Y., Grote M., et al., “Characterization of Der p 21, a New Important Allergen Derived From the Gut of House Dust Mites,” Allergy 63, no. 6 (2008): 758–767, 10.1111/j.1398-9995.2008.01647.x. [DOI] [PubMed] [Google Scholar]
- 44. Garib V., Trifonova D., Freidl R., et al., “Milk Allergen Micro‐Array (MAMA) for Refined Detection of Cow's‐Milk‐Specific IgE Sensitization,” Nutrients 15, no. 10 (2023): 2401, 10.3390/nu15102401. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45. Breiteneder H., Pettenburger K., Bito A., et al., “The Gene Coding for the Major Birch Pollen Allergen Betv1, Is Highly Homologous to a Pea Disease Resistance Response Gene,” EMBO Journal 8, no. 7 (1989): 1935–1938, 10.1002/j.1460-2075.1989.tb03597.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46. Akinfenwa O., Huang H. J., Linhart B., et al., “Preventive Administration of Non‐Allergenic Bet v 1 Peptides Reduces Allergic Sensitization to Major Birch Pollen Allergen, Bet v 1,” Frontiers in Immunology 12 (2021): 744544, 10.3389/fimmu.2021.744544. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47. Liu X., Zheng P., Zheng S. G., et al., “Co‐Sensitization and Cross‐Reactivity of Blomia tropicalis With Two Dermatophagoides Species in Guangzhou, China,” Journal of Clinical Laboratory Analysis 33, no. 9 (2019): e22981, 10.1002/jcla.22981. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48. García E., Ardila J.‐C., Crespo N., et al., “Selection of Allergen Extract for Immunotherapy in Polysensitized Allergic Rhinitis Patients,” Immunotherapy 16, no. 9 (2024): 623–634, 10.1080/1750743X.2024.2342225. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49. Thomas W. R., Smith W. A., and Hales B. J., “The Allergenic Specificities of the House Dust Mite,” Chang Gung Medical Journal 27, no. 8 (2004): 563–569. [PubMed] [Google Scholar]
- 50. Casset A., Mari A., Purohit A., et al., “Varying Allergen Composition and Content Affects the In Vivo Allergenic Activity of Commercial Dermatophagoides pteronyssinus Extracts,” International Archives of Allergy and Immunology 159, no. 3 (2012): 253–262, 10.1159/000337654. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51. Wollmann E., Lupinek C., Kundi M., Selb R., Niederberger V., and Valenta R., “Reduction in Allergen‐Specific IgE Binding as Measured by Microarray: A Possible Surrogate Marker for Effects of Specific Immunotherapy,” Journal of Allergy and Clinical Immunology 136, no. 3 (2015): 806–809.e7, 10.1016/j.jaci.2015.02.034. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52. Lupinek C., Wollmann E., and Valenta R., “Monitoring Allergen Immunotherapy Effects by Microarray,” Current Treatment Options in Allergy 3 (2016): 189–203, 10.1007/s40521-016-0084-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
FIGURE S1: Coomassie Brilliant Blue‐stained SDS‐PAGE containing different amounts (Lanes: 5, 10, 15, 20 μg) of Blomia tropicalis (Blo t), Dermatophagoides (Der p) protein extracts and a molecular weight marker (Lane M). Molecular weights (kDa) are indicated on the left margin.
FIGURE S2: Alignments of the amino acids sequences of Blo t 2 (GenBank: AAQ73483.1) and Der p 2 (GenBank: AAF86462.1) (A), Blo t 5 (GenBank: AAD10850.1) and Der p 5 (GenBank: AAB32842.1) (B), Blo t 8 (GenBank: ACV04860.1) and Der p 8 (GenBank: AAB32224.1) (C), Blo t 10 (GenBank: ABU97466.1) and Der p 10 (GenBank: CAA75141.1) (D), and Blo t 21 (GenBank: AAX34047.1) and Der p 21 (GenBank: ABC73706.1) (E). Identical amino acids are indicated by dashes, gaps by dots and different amino acids by colours (red: acidic hydrophilic; yellow: neutral; green: basic hydrophilic; blue: hydrophobic). Numbers of amino acids are displayed on the right margin.
FIGURE S3: Coomassie Brilliant Blue‐stained SDS‐PAGE (A) containing purified recombinant B. tropicalis allergens (Lanes: Blo t 2, Blo t 5, Blo t 8, Blo t 10, Blo t 12, Blo t 13, Blo t 21). Molecular weights (kDa) are indicated on the left margin (M). Mass Spectrometry (MALDI) analysis of recombinant Blo t allergens (Blo t 2, Blo t 5, Blo t 8, Blo t 10, Blo t 12, Blo t 13, Blo t 21) (B). X‐axes show molecular masses (Dalton) and y‐axes signal intensities. Circular Dichroism analysis of the aforementioned Blo t allergens (C). Mean residue ellipticities (y‐axes) are shown for different wavelengths (x‐axes).
FIGURE S4: Outlay of the allergen microarray. Indicated are guide dot triplicates (empty circles, top) and positions of the spotted allergen triplicates.
FIGURE S5: IgG reactivity (y‐axis: ISU IgG corresponding to IgG levels) of HDM‐sensitised patients from Blo t endemic (full dots, left) and Blo t‐non‐endemic regions (open circles, right) to Blomia tropicalis allergens (A) and Dermatophagoides allergens (B) (x‐axes). Horizontal red bars indicate the median values whereas the dashed horizontal lines indicade the cut‐offs. Significant differences between patients are indicated (*p < 0.05, **p < 0.01, ***p < 0.001, Mann–Whitney U test).
TABLE S1: Demographic and clinical characterisation of HDM‐sensitised patients from Blo t‐endemic regions.
TABLE S2: Demographic and clinical characterisation of HDM‐sensitised patients from Blo t‐non‐endemic regions.
TABLE S3: Heat map of IgE reactivity of HDM‐sensitised patients from Blo t‐endemic regions (#1–115) to Blomia tropicalis and Dermatophagoides pteronyssinus allergens (Der p 1, Blo t 2, Der p 2, Der p 4, Blo t 5, Der p 5, Der p 7, Blo t 8, Der p 8, Blo t 10, Der p 10, Blo t 12, Blo t 13, Der p 18, Der p 20, Blo t 21, Der p 21, Der p 23, Der p 29, Der p 37). Colour codes for IgE levels are indicated at the bottom of the table. ISU, international standardised unit; ND, not done.
TABLE S4: Heat map of IgE reactivity of HDM‐sensitised patients from Blo t‐non‐endemic regions (#116–148) to Blomia tropicalis and Dermatophagoides pteronyssinus allergens (Der p 1, Blo t 2, Der p 2, Der p 4, Blo t 5, Der p 5, Der p 7, Blo t 8, Der p 8, Blo t 10, Der p 10, Blo t12, Blo t 13, Der p 18, Der p 20, Blo t 21, Der p 21, Der p 23, Der p 29, Der p 37). Colour codes for IgE levels are indicated at the bottom of the table. ISU, international standardised unit; ND, not done.
TABLE S5: Heat map of IgG reactivity of HDM‐sensitised patients from Blo t‐endemic regions (#1–115) to Blomia tropicalis and Dermatophagoides pteronyssinus allergens (Der p 1, Blo t 2, Der p 2, Der p 4, Blo t 5, Der p 5, Der p 7, Blo t 8, Der p 8, Blo t 10, Der p 10, Blo t12, Blo t 13, Der p 18, Der p 20, Blo t 21, Der p 21, Der p 23, Der p 29, Der p 37).). Colour codes for IgG levels are indicated at the bottom of the table. ISU IgG, international standardised unit; ND, not done.
TABLE S6: Heat map of IgG reactivity of HDM‐sensitised patients from Blo t‐non‐endemic regions (#116–148) to Blomia tropicalis and Dermatophagoides pteronyssinus allergens (Der p 1, Blo t 2, Der p 2, Der p 4, Blo t 5, Der p 5, Der p 7, Blo t 8, Der p 8, Blo t 10, Der p 10, Blo t12, Blo t 13, Der p 18, Der p 20, Blo t 21, Der p 21, Der p 23, Der p 29, Der p 37). Colour codes for IgG levels are indicated at the bottom of the table. ISU IgG, international standardised unit; ND, not done.
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
